更新于：2024-11-01

Long Qt Syndrome 2

QT间期延长综合征2

更新于：2024-11-01

基本信息

别名

LONG QT SYNDROME 2、LQT2、LQT2 syndrome

+ [4]

简介

An autosomal dominant condition caused by mutation(s) in the KCNH2 gene, encoding potassium voltage-gated channel subfamily H member 2. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.

关联

项与 QT间期延长综合征2 相关的药物

LQT-1213

靶点

SGK1

作用机制

SGK1 inhibitors

在研机构

Thryv Therapeutics, Inc.初创企业

原研机构

Thryv Therapeutics, Inc.初创企业

在研适应症

QT间期延长综合征2 [+2]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

Eleclazine

靶点

Nav1.5

作用机制

Nav1.5阻滞剂

在研机构-

原研机构

Gilead Sciences, Inc.

在研适应症-

非在研适应症

稳定型心绞痛 [+8]

最高研发阶段终止

首次获批国家/地区-

首次获批日期1800-01-20

项与 QT间期延长综合征2 相关的临床试验

NCT05906732 / Recruiting临床1/2期

A Phase 1b/2a, 2-Part Study; Part 1: Randomized, Double-Blind, Crossover, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGK-1 Kinase Inhibition by LQT-1213 on Dofetilide-Induced QTc Prolongation in Healthy Adult Subjects. Part 2: Single-Blind, Multiple-Dose, Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LQT-1213 in Patients Diagnosed With Type 1, 2 or 3 Long QT Syndrome

Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy subjects, with screening procedures within 28 days of enrolment.
Part 2: This is a Phase 2a, single-blind, placebo run-in, multiple-dose safety study to evaluate the safety, tolerability, and PK of LQT-1213 in patients diagnosed with LQT1, LQT2 or LQT3. Up to 12 participants with LQT1, up to 20 participants with LQT2 and up to 12 participants with LQT3 will be recruited.

开始日期2023-03-12

申办/合作机构

Thryv Therapeutics, Inc.初创企业

NCT02365506 / Completed临床1期

A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome

The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.

开始日期2015-07-20

申办/合作机构

Gilead Sciences, Inc.

NCT01745666 / Unknown statusN/AIIT

Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients With KCNQ1 or KCNH2 Mutation Without Long QT Interval in Rest ECG

The aim of the study is to evaluate the best stress exam to unmask long QT in patient with KCNQ1 or KCNH2 mutation without long QT interval in rest electrocardiogram.

开始日期2012-05-01

申办/合作机构

Nantes University Hospital

100 项与 QT间期延长综合征2 相关的临床结果

登录后查看更多信息

100 项与 QT间期延长综合征2 相关的转化医学

登录后查看更多信息

0 项与 QT间期延长综合征2 相关的专利（医药）

登录后查看更多信息

621

项与 QT间期延长综合征2 相关的文献（医药）

2024-12-01·Stem Cell Research

Establishment of a human-induced pluripotent stem cell line from a long QT syndrome type 2 patient harboring a KCNH2 mutation

Article

作者: Yun, Nuri ; Mi Hwang, You ; Kang, Ji-Young ; Park, Malgeum ; Mun, Dasom ; Yoo, Gyeongseo ; Kim, Hyoeun ; Joung, Boyoung

Long QT syndrome type 2 (LQT2) is a heart disorder resulting from a loss-of-function mutation in theKCNH2gene that causes loss of Kv11.1 channel function, potentially resulting in syncope, arrhythmias, and sudden death. We derived induced pluripotent stem cell line from PBMC of LQT2 patient carrying a variant of pathogenic variant (c.157G > A; p.Gly53Ser). The generation of iPSC lines was achieved using the non-integrative Sendai virus-mediated iPSC reprogramming method. The iPSC cell line exhibit pluripotency, normal karyotype, stem cell morphology, and differentiation capability, resulting a reliable cell source to study the effects of KCNH2 mutation in disease-specific cell types.

2024-10-10·Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

[Clinical and genetic analysis of a Chinese pedigree affected with type 2 Long QT syndrome due to variant of KCNH2 gene].

Article

作者: Yan, Lijie ; Liu, Jingjing ; Xu, Xizheng ; Sun, Meng ; Chen, Xiaosheng ; Wu, Jintao ; Yang, Haitao ; Hu, Juan

OBJETIVETo explore the clinical and genetic etiology of a Chinese pedigree affected with type 2 Long QT syndrome (LQTS).METHODSA pedigree with type 2 LQTS presented at Fuwai Central China Cardiovascular Hospital on August 23, 2019 was selected as the study subject. Peripheral blood samples were collected from the proband and her parents. Following extraction of genomic DNA, whole exome sequencing (WES) was carried out for the proband, and candidate variant was screened through functional annotation and protein-protein interaction (PPI) analysis. Sanger sequencing was conducted to verify the pathogenicity of candidate variant. This study was approved by the Fuwai Central China Cardiovascular Hospital (Ethics No. 2019-15).RESULTSWES revealed that the proband has harbored a missense variant of the KCNH2 gene, namely c.1478A>G (p.Tyr493Cys), which was confirmed by Sanger sequencing to have inherited from her father. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as likely pathogenic (PM2_supporting+PM5+PP3+PP4).CONCLUSIONThe KCNH2 gene c.1478A>G (p.Tyr493Cys) variant probably underlay the type 2 LQTS in this pedigree.

2024-10-01·Ultrasound in Obstetrics & Gynecology

Isolated non‐immune‐mediated second‐degree atrioventricular block in the fetus: natural history and predictive factors for spontaneous recovery

Article

作者: Wang, C. ; Liao, H. ; Hua, Y. ; Dai, X. ; Zhou, S. ; Shao, S. ; Zhou, K. ; Li, Y. ; Yu, H. ; Zhu, Q.

ABSTRACTObjectivesTo determine the clinical course of fetal isolated non‐immune‐mediated second‐degree atrioventricular block (AVB) and the factors associated with spontaneous recovery in these cases.MethodsFetuses with isolated non‐immune‐mediated second‐degree AVB were recruited prospectively between 2014 and 2022. These fetuses were divided into two groups: those which recovered spontaneously and those which did not. Maternal and fetal characteristics and intrauterine and postnatal outcomes were compared between the two groups.ResultsThe study cohort included 20 fetuses with isolated non‐immune‐mediated second‐degree AVB, diagnosed at a median gestational age of 22.0 (range, 17.0–35.0) weeks. In 12 fetuses, 1:1 atrioventricular conduction was restored spontaneously in utero and there was no recurrence during the postnatal follow‐up period. In the remaining eight fetuses, second‐degree AVB was maintained and, in six of these, the pregnancy was terminated on parental request. Of the two liveborn children who had persistent second‐degree AVB prenatally, one had progressed to complete AVB at the latest follow‐up, at the age of 34 months, but was asymptomatic, without heart enlargement or dysfunction. The other child progressed to complete AVB after delivery and was diagnosed with type‐2 long QT syndrome. This infant died aged 2 months. Fetuses in the group that recovered spontaneously had earlier gestational age at diagnosis (median, 20.0 (range, 17.0–26.0) vs 24.5 (range, 18.0–35.0) weeks; P = 0.004) and higher atrial rate at diagnosis (median, 147 (range, 130–160) vs 138 (range, 125–149) bpm; P = 0.006) in comparison with the group that did not recover spontaneously. The best cut‐off values for prediction of failure to recover spontaneously were 22.5 weeks' gestational age at diagnosis and 144 bpm atrial rate at diagnosis, with sensitivities of 87.5% and 75.0%, respectively, and specificities of 92.0% and 87.5%, respectively.ConclusionsThe outcome of 60% of fetuses with isolated non‐immune‐mediated second‐degree AVB was favorable. Earlier gestational age and higher atrial rate at diagnosis were associated with spontaneous reversion to normal sinus rhythm. Prenatal genetic testing should be performed in cases with persistent AVB, to exclude heritable disorders including long QT syndrome. These findings provide important information for clinical management and prenatal counseling in these cases. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

项与 QT间期延长综合征2 相关的新闻（医药）

2024-05-15

·FierceBiotech

BioMarin sheds 170 jobs in wake of narrowed R&D refocus

The majority of affected employees were notified yesterday, BioMarin said. BioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed that 170 employees are also leaving the building as part of the R&D restructure. The Voxzogo and Roctavian maker revealed last month that it was halting four programs including BMN 331, a gene therapy being assessed in a phase 1/2 trial for patients with hereditary angioedema, and BMN 255, which was being evaluated in a phase 1 trial for metabolic dysfunction-associated steatohepatitis (MASH). Two preclinical programs were also terminated: a monoclonal antibody called BMN 355 designed to treat long-QT syndrome types 2 and 3; and BMN 365, which was targeted at plakophilin-2 mutations and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Instead, the company is focusing on three programs that “met the highest bar for advancement.” They include BMN 351, a next-gen oligonucleotide in a phase 1/2 trial for patients with Duchenne muscular dystrophy, as well as BMN 349, a phase 1-stage oral small molecule for alpha-1 antitrypsin deficiency-associated liver disease. The final program to have been spared the ax is BMN 333, a preclinical C-type natriuretic peptide being developed for multiple growth disorders. The job cuts represent around 5% of the company’s workforce and are related to this “portfolio assessment,” a BioMarin spokesperson told Fierce Biotech in an emailed statement yesterday. The layoffs, which the company’s management agreed on last week, are likely to incur pre-tax charges of around $15 to $20 million during the second quarter as a result of severance and other employee termination benefits, BioMarin explained in a SEC filing (PDF). The majority of affected employees were notified yesterday, with the layoffs likely to be completed by the end of July, according to the filing. “We are grateful to the impacted employees for their dedication to our mission of developing transformative medicines for patients,” the spokesperson told Fierce Biotech. “BioMarin is committed to providing support through this transition for those employees impacted.” While BioMarin didn’t explicitly refer to any layoffs when the strategic rethink was outlined during first-quarter earnings in April, the company did say at the time that the pipeline restructure would save up to $60 million in R&D costs this year, offset by up to $20 million that will be spent on accelerating the prioritized programs.

基因疗法寡核苷酸临床1期

2022-06-11

·Insight数据库

ASCO 2022丨戈沙妥珠单抗凭什么领跑 Trop-2 ADC 赛道？

随着 DESTINY-Breast04 惊艳亮相 2022 年 ASCO 全体大会，同步登顶 NEJM：T-DXd 与化疗相比，在 HER2 低表达晚期乳腺癌患者中将疾病进展或死亡风险降低 50%，有望改变乳腺癌患者治疗模式，同时，让 T-DXd 等新一代 ADC 类药物再度成为了关注的焦点和讨论的热点，这类药物独具「魔法子弹」般抗肿瘤效果，取得了一系列鼓舞人心的研究结果，成为了新希望。（图源自参考文献 1） TROP-2：赓续鼎新志高远TROP-2 是一种 I 型跨膜糖蛋白，在 80% 的乳腺癌患者中高表达，且与肿瘤进展和不良预后有关，这使得 TROP-2 在乳腺癌治疗领域成为一个很好的靶点。戈沙妥珠单抗（Sacituzumab Govitecan，SG）是由靶向 TROP-2 抗原的人源化 IgG1 抗体与化疗药物伊立替康（一种拓扑异构酶 I 抑制剂）的代谢活性产物 SN-38 偶联而成，DAR 高达 7.6：1。基于 ASCENT 等研究结果，SG 现已被 FDA 批准用于既往接受过至少 2 种全身治疗的晚期三阴性乳腺癌患者，其中至少 1 线用于转移性疾病。同时，多项研究对 SG 用于早期三阴性乳腺癌进行了积极的探索，以期让更多病人更早从中获益。本次大会公布了 NeoSTAR 研究中 SG 单药队列的结果，该研究是一项评估 SG 用于新辅助治疗 TNBC 的 II 期研究，包括两个队列：即 SG 单药队列和 SG 联合帕博利珠单抗治疗队列。（图源 2022 ASCO 大会）研究纳入 T1c-T4（任何 N）三阴性乳腺癌患者，给予 SG 进行 4 周期的新辅助治疗，4 个周期后经活检证实有残留病灶的患者可根据医师的选择更换药物接受额外的新辅助治疗。主要研究终点为病理性完全缓解率（pCR 率），次要研究终点包括影像学缓解率、安全性、耐受性及无事件生存期（EFS）。（图源 2022 ASCO 大会）研究共纳入 50 例患者（中位年龄 = 48.5 岁），其中 49 例完成了 4 个周期的 SG 新辅助治疗，29 例在 4 周期 SG 新辅助治疗后接受手术。结果发现，SG 单药新辅助治疗的 pCR 率为 30%（n = 15/50, 95% CI：18%-45%），而其他 14 名患者分别为 RCB-1（n = 3）、RCB-2（n = 7）和 RCB-3（n = 4）。在 21 例接受了额外新辅助治疗的患者中，7 例达到 pCR。值得惊喜的是，在 8 例胚系 BRCA 突变的患者中，7 例在 SG 新辅助治疗后接受手术，6 例（75%）患者达到 pCR。在安全性方面，该研究的安全性数据与既往研究一致，常见为 1-2 级不良反应，包括恶心、乏力、脱发、中性粒细胞减少、贫血及皮疹。在这个首次使用 ADC 进行的 TNBC 新辅助治疗的 NeoSTAR 研究中，SG 单药显示出令人鼓舞的临床活性和安全性，但仍需进一步研究 SG 的最佳使用时长以及包括免疫疗法在内的新辅助治疗联合策略。在 IMMU-132-01 I/II 期篮子试验中，SG 在晚期 HR+/HER2-乳腺癌治疗中也展现出的抗肿瘤活性：ORR = 31.5%（CDK4/6i 经治亚组 ORR = 25%），中位 PFS 为 5.5 个月（95% CI：3.6-7.6 个月），中位 OS 达 12 个月（95% CI：9.0-18.2 个月），不良反应同既往研究一致，可防可控。因而促使了在更大样本中探索 SG 治疗 HR+/HER2- 患者的疗效及安全性。TROPiCS-02 是一项一项双臂、开放标签、全球多中心的 III 期临床研究，探索 SG 在接受过内分泌、CDK4/6 抑制剂及紫杉烷治疗，以及晚期 2-4 线化疗的 HR+/HER2-乳腺癌患者中的疗效和安全性。（图源 2022 ASCO 大会）该研究入组 543 例患者，按照 1：1 随机接受 SG（10 mg/kg，iv，第 1 和 8 天，21 天/周期）治疗或医生选择的化疗方案（TPC：卡培他滨、长春瑞滨、吉西他滨或艾立布林）组，直至疾病进展或不可耐受。主要终点是基于盲态独立中心评估（BICR）的无进展生存期（PFS），次要终点包括盲态独立中心评估和研究者评估的总生存期（OS）、客观缓解率（ORR）、缓解期（DoR）和临床获益率（CBR），患者报告结果和安全事件。并根据是否有内脏转移、晚期内分泌治疗时间是否超过 6 个月、既往晚期化疗线数（2 vs 3/4），进行分层分析。（图源 2022 ASCO 大会）共计入组 543 例患者，SG 组和 TPC 组分别入组 272 例和 271 例患者。两组患者的人口学和临床特征相似。患者中位年龄分别为 57 岁（SG 组）和 55 岁（TPC 组）；95% 患者存在内脏转移；基线肝转移患者约占 85%。86% 的患者在晚期使用过 ≥6 个月的内分泌治疗；约 60% 的患者 CDK4/6 抑制剂治疗时长不超过 1 年。99% 的患者在晚期接受 CDK4/6 抑制剂治疗。大部分病人在晚期接受过靶向治疗（SG 组 67%，化疗组 63%），主要包括 PARPi、mTORi、PI3Ki、BETi、AKTi、AAKi 及其它激酶抑制剂、ADC 等药物。两组患者均接受过中位 3 线全身化疗，主要包括卡培他滨、紫杉醇和艾立布林。结果显示，与 TPC 组相比，SG 可为病人带来显著的生存获益，降低 34% 的疾病进展或死亡风险，中位 PFS 分别为 5.5 个月 vs 4.0 个月（HR = 0.66，95% CI: 0.53-0.83，P<0.0003）。亚组分析显示，SG 与 TPC 相比，无论是否有内脏转移、晚期内分泌治疗是否超过 6 个月、既往化疗线数、年龄、ECOG 评分和 CDK4/6 抑制剂治疗时长，都显示出了全面获益。这些治疗预后不佳的患者，均可从 SG 中获得生存获益。同时，SG 还可带来总生存 OS 的改善趋势，但数据仍未成熟，有待进一步随访。在客观缓解率 ORR（21% vs 14%，P = 0.03）和临床获益率 CBR（34% vs 22%，P = 0.002）方面，SG 组均显著高于 TPC 组。在安全性方面，本次分布的安全性数据与已知的安全性特征一致。同时，与 TPC 相比，SG 可明显改善患者的生活质量。对于多线经治的 HR+/HER2-晚期乳腺癌，SG 与 TPC 组相比，在 PFS 和 OS 表现出具有重要的临床意义改善的结果，且各亚组呈现一致的获益，包括接受 ≥3 线化疗，既往 CDK4/6i 使用及内脏转移的病人，且安全性与已知的安全性特征一致，还能显著提升患者的生活质量。TROPiCS-02 研究显示对于多线治疗的晚期 HR+/HER2- 乳腺癌患者，SG 的总体获益大于风险，成为这类治疗选择有限的患者的一种重要的新治疗选择。讨论目前 TNBC 的新辅助治疗方案以蒽环联合紫杉类药物为主，可达约 40% 的 pCR 率。在 NeoSTAR 研究中，大胆地将 SG 单药新辅助治疗，仅 4 周期就可获得 30% 的 pCR 率，尽管设计为单臂研究，但也更凸显了该药独特的机制和抗肿瘤作用，十分具有创新性。随着免疫治疗、PARPi 等药物在 TNBC 新辅助研究等的相继成功，NeoSTAR 的积极结果再一次丰富了 TNBC 新辅助治疗的手段，尤其对于 TNBC 免化疗模式或者精准治疗的优化探索，其深远意义更值得我们思考。同时，研究发现 ADC 类药物治疗阶段，会对肿瘤微环境进行重塑，如 TILs 显著增加，从而使得联合免疫治疗达到协同作用，NeoSTAR 研究中的 SG 联合帕博利珠单抗队列的结果非常值得期待。另外，该研究样本量小，其结论需更大样本量来进行证实；SG 所带来的 pCR 的改善，需要生存预后的检验，远期生存疗效的结果也是非常值得关注。优势人群的筛选：该研究中 8 例有胚系 BRCA 突变患者的 pCR 率高达 75%，远高于 TBCRC-031（INFORM）研究中标准化疗的 pCR 率（不足 30%）；结合 ASCENT 研究探索性分析发现胚系 BRCA 突变患者接受 SG 治疗可延长生存约 10 个月（OS：15.6 个月 vs 4.4 个月），而无胚系 BRCA 突变的患者接受 SG 治疗仅延长 3 个月，提示胚系 BRCA 突变可能是 SG 的预测生物标志物，但其还需更大样本来证实和探索具体机制。HER3-TDXd：千锤万凿出深山ErbB3 (HER3) 是 HER 家族的成员，在各种肿瘤中普遍表达，约 30-50% 乳腺癌表达 HER3，与肿瘤的发生、发展和患者预后都密切相关，成为潜在的治疗靶点。但靶向 HER3 的单克隆抗体的活性有限，且 HER3 几乎没有胞内酪氨酸激酶活性，而不易被小分子抑制剂阻断，因而针对 HER3 的靶向治疗多年未有突破，屡屡失败。全球首款 HER3 的新一代 ADC 药物 Patritumab deruxtecan（HER3-TDXd）是由靶向 HER3 的全人源免疫球蛋白 G1 单克隆抗体 patritumab、稳定的可裂解四肽 Linker 和拓扑异构酶 I 抑制剂（依沙替康衍生物）组成，成为了靶向 HER3 的新期待。Ian E. Krop 教授在本次大会上公布了 I/II 期研究 U31402-A-J101 的研究结果，该研究旨在评估 Patritumab deruxtecan（HER3-TDXd）在 HER3 表达的转移性乳腺癌中的疗效和安全性。（图源 2022 ASCO 大会）该研究纳入了多线治疗后的患者，包括 113 例 HR+/HER2-患者，53 例 TNBC 患者及 14 例 HER2+患者。研究中进行了剂量递增、剂量探索和剂量扩展队列三个阶段。HER3 高表达定义为 ≥75% 的膜阳性，低表达定义为 25%～75% 的膜阳性。基线数据显示 TNBC 患者的中位治疗线数为 2（1-13），HR+/HER2- 患者的中位治疗线数为 6（2- 13）， HER2+ 患者的中位治疗线数为 5.5（2-11）。90.3% 的 HR+/HER2-患者、85.7% 的 HER2+ 患者和 64.2% 的 TNBC 患者存在肺和/或肝转移。（图源 2022 ASCO 大会）研究结果表明：中位随访 31.9 个月，中位治疗时长 5.9 个月，HER3-TDXd 表现出持久的抗肿瘤活性，ORR = 28.6%（95%CI：22.1%-35.7%），中位 DOR 为 7 个月（95%CI：5.5-8.5 个月）。在不同的分子分型中均展现优异的疗效：HR+/HER2-患者：ORR = 30.1%, 中位 DOR 为 7.2 个月，中位 PFS 为 7.4 个月）TNBC 患者：ORR = 22.6%, 中位 DOR 为 5.9 个月，中位 PFS 为 5.5 个月）HER2+患者：ORR = 42.9%, 中位 DOR 为 8.3 个月，中位 PFS 为 11.0 个月）。（图源 2022 ASCO 大会）基线 HER3 的表达水平不论表达高低与疗效未呈现出明显的相关性，并且在治疗的过程中，HER3 膜表达水平呈显著的动态变化，且变化模式与治疗疗效并未发现相关性。总体来说，HER3-TDXd 的毒性可控，仅 9.9% 的病人因治疗相关不良反应而导致停药。最常见不良反应是胃肠道反应和血液学毒性。出现 ≥ 3 级中性粒细胞减少症、血小板减少症和白细胞减少症的风险随剂量增加而增加，但可通过延迟治疗或药物减量得以控制。6.6% 的患者发生治疗相关的间质性肺病（ILD），大多为 1/2 级。展望未来，Patritumab deruxtecan 正有多项乳腺癌临床试验中进行探索，具较大的临床应用前景，未来可期。讨论靶向 HER3 的肿瘤药物研发屡屡失败，至今仍没有药物上市，目前处于临床研究阶段的热点主要是 HER3 双靶点双特异性抗体和靶向 HER3 的 ADC 类药物。由于 HER3 主要通过与 EGFR 或 HER2 形成异源二聚体，从而激活 PI3K/AKT、MAPK、JAK/STAT 等信号通路，从而参与肿瘤的发生发展。HER3 双靶点双特异性抗体的一个臂与 HER2 或 EGFR 受体结合，另一个臂有效阻断 HER3 与其配体 NRG1 或 NRG1 融合蛋白相互作用，从而发挥抗肿瘤作用，但目前在乳腺癌领域 HER3 双靶点双特异性抗体未有突破性进展。HER3-DXd 是目前唯一进入 II 期研究的 ADC，在 U31402-A-J101 研究中，HER3-DXd 显示出 ORR 和 PFS 的获益，但其有效性和安全性需要更多的数据来证实。且探索性分析发现疗效与 HER3 的基线水平和动态变化无明显的相关性，提示如何筛选真正获益的人群，以及生物标记物 HER3 的价值也等待解答。✩ 本文仅供医疗卫生等专业人士参考本文首发于丁香园肿瘤时间策划：GoEun，梅浙投稿及合作：yinqihang@dxy.cn题图来源：站酷海洛PLUS参考文献1. Fu ZW, Li SJ, Han SF, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038/s41392-022-00947-7.2. Krop IE, et al. 2022 ASCO, Abs 1002.3. Spring L, et al. 2022 ASCO, Abs 512.4. Rugo HS, et al. 2022 ASCO, AbsLBA1001.

ASCO会议抗体抗体药物偶联物免疫疗法小分子药物